𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators

✍ Scribed by Akane Kizu; Atsushi Shioi; Shuichi Jono; Hidenori Koyama; Yasuhisa Okuno; Yoshiki Nishizawa

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
166 KB
Volume
93
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Although lipid‐lowering therapy with 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) decreases the progression of coronary artery and aortic valve calcification, the mechanism of action of these drugs to inhibit the calcification process remains unclear. In this study, we investigated the effect of statins such as cerivastatin and atorvastatin on vascular calcification by utilizing an in vitro model of inflammatory vascular calcification. Cerivastatin and atorvastatin dose‐dependently inhibited in vitro calcification of human vascular smooth muscle cells (HVSMCs) induced by the following inflammatory mediators (IM): interferon‐γ, 1α,25‐dihydroxyvitamin D~3~, tumor necrosis factor‐α, and oncostatin M. These statins also depressed expression of alkaline phosphatase (ALP) in HVSMCs induced by these factors. Mevalonate and geranylgeranylpyrophosphate reversed the inhibitory effect of cerivastatin on ALP expression in HVSMCs, while farnesylpyrophosphate showed no effect on the ALP activities inhibited by this drug, suggesting that inhibition of Rho and its downstream target, Rho kinase may mediate the inhibitory effect of cerivastatin. Cerivastatin prevented RhoA activation in HVSMCs induced by the IM. A specific inhibitor of Rho kinase (Y‐27632) inhibited in vitro calcification and induction of ALP in HVSMCs. These findings provide a possible mechanism of statins to prevent the progression of calcification in inflammatory vascular diseases such as atherosclerosis and cardiac valvular calcification. © 2004 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Fibronectin enhances in vitro vascular c
Fibronectin enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells via ERK pathway
✍ Hai-Tao Ding; Chen-Guang Wang; Tian-Lan Zhang; Kui Wang 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

## Abstract The process of vascular calcification presents several features similar to osteogenesis in which fibronectin (FN) acts as a regulator of osteoblastic differentiation and the ERK signal pathway is involved. In order to find whether FN promotes the osteoblastic differentiation of vascular

Inhibition of PDGF-stimulated and matrix
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors
✍ Kouros Motamed; Sarah E. Funk; Hidenori Koyama; Russell Ross; Elaine W. Raines; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

## Abstract Interactions among growth factors, cells, and extracellular matrix regulate proliferation during normal development and in pathologies such as atherosclerosis. SPARC (secreted protein, acidic, and rich in cysteine) is a matrix‐associated glycoprotein that modulates the adhesion and prol

ERK1/2 mediates TNF-α-induced matrix met
ERK1/2 mediates TNF-α-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-κB and AP-1: Involvement of the ras dependent pathway
✍ Sung-Kwon Moon; Byung-Yoon Cha; Cheorl-Ho Kim 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB 👁 1 views

## Abstract The expression of matrix metalloproteinase‐9 (MMP‐9) has been implicated in progression of atherosclerotic lesions. The role and importance of the signaling pathway in the transcriptional regulation of MMP‐9 in human aortic smooth muscle cells (HASMC) was examined. Tumor necrosis factor